hVIVO is now offering major employee groups a best-in-class COVID-19antibody test, with the highest level of accuracy available. Serviced from our laboratory in London it ensures that your employees are

The first four of eight nominees in the International category of the EY Entrepreneur of the Year competition are profiled this week. The awards are run in association with Julius Baer, Enterprise Ireland,

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has

Our over-reliance on antibiotics to find relief from numerous ailments, including cold and flu symptoms, is a major health concern – according to the Centers for Disease Control and Prevention.

Q: Can we just spend a couple of minutes on COVID 19? Is AstraZeneca engaged in your challenge study model? Cathal Friel Unfortunately, we are precluded from talking about anybody,

The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine. The Long Island-based team has developed a vaccine made from a live version

A tiny Long Island biotechnology startup in a global race to develop a COVID-19 vaccine has rolled out plans for a human trial. The Phase 1 trial using about 50 paid young adult volunteers will evaluate the

Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to  provide a respiratory syncytial virus (RSV) human challenge study trial. The Dublin-listed

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has